Skip to Main Content

IND/IDE Support

YCCI provides a comprehensive, centralized resource for FDA submission of Investigational New Drug (IND) applications and Investigational Device Exemptions (IDEs), whose staff members have industry experience.

Policy Regarding Sponsor-Investigator held IND, IDE or EUA-related protocols

Effective May 1, 2021, a Yale Investigator who intends to conduct an investigation/project that requires they hold an IND, IDE or EUA must submit for review to the YCCI IND/IDE Management Office. The Office must receive IND, IDE, and EUA applications before (or in the case of emergency expanded/compassionate use requests, contemporaneously with) their submission to the FDA and the Yale HRPP for IRB review, as applicable. Submissions of proposals to the HRPP requiring an IND or IDE that have not been previously reviewed or approved by the Office will be routed to the Office by the HRPP prior to IRB review and approval.

Read the full policy here.

To whom does the policy apply?

Investigators at the Yale School of Medicine who hold, or are considering holding with the US Food and Drug Administration (FDA):

  • Investigational New Drug Applications (INDs) including Compassionate use/Expanded access
  • Investigational Device Exemptions (IDEs) including Compassionate use/Expanded access
  • Emergency Use Authorizations (EUA)
For assistance, contact Amy Hummel at the YCCI IND/IDE Management Office for guidance by emailing amy.hummel@yale.edu.

The ideal time to contact the IND/IDE service is before a research protocol is finalized; consulting with these experts while still in the preparatory phase will ensure that investigators obtain the appropriate data needed for an IND application.

Staff in the IND/IDE Management Office collaborate closely with other YCCI functional groups providing Sponsor support for trials such as: Project Management, Data Management, Monitoring, and Data Safety Monitoring Board, as well as the Yale HRPP.

Services provided by this unit include:

  • IND exemption determinations
  • Significant Risk vs Non-Significant Risk vs IDE exemption determinations
  • Research INDs and Significant Risk IDEs:
    • Initial applications
    • Protocol amendments
    • IND Safety Reports/UADE Reports
    • Annual Reports
    • Final Reports
    • Other document updates
  • Clinical Hold Responses
  • Pre-IND/Q-Sub feedback
  • Expanded Access requests (including emergency, single-patient, and multi-patient)